The concentrations of fecal and serum bile acids (BAs) are known to be altered in human patients with chronic liver diseases (CLDs), especially those with biliary tract involvement (BTD). Scarce literature is available regarding fecal BA modifications during canine CLDs. This study aimed to evaluate fecal BAs in canine CLDs according to different clinical and clinicopathological variables. Forty-six dogs were enrolled. Canine feces were analyzed by HPLC. Cholic Acid (CA), Chenodeoxycholic Acid (CDCA), Ursodeoxycholic Acid (UDCA), Deoxycholic Acid (DCA), and Lithocholic Acid (LCA) were measured, and primary BAs (CA + CDCA), secondary BAs (UDCA + DCA + LCA), and the primary/secondary (P/S) ratio were calculated. Primary BAs (p < 0.0001), CA (p = 0.0003), CDCA (p = 0.003), the P/S ratio (p = 0.002), and total BAs (p = 0.005) were significatively higher in BTD dogs (n = 18) compared to in non-BTD dogs (n = 28). Fecal secondary BAs did not statistically differ between BTD and non-BTD dogs. Gastrointestinal clinical signs (p = 0.028) and diarrhea (p = 0.03) were significantly more prevalent in BTD dogs compared to in non-BTD dogs, supporting the hypothesis of some pathological mechanisms assimilable to bile acid diarrhea (BAD). Our results could reflect imbalances of the fecal BA metabolism in dogs with CLDs. Further studies involving gut microbiome and metabolomic assessment are needed to better understand the possible clinical implications of BA metabolism disruption and their potential role in canine CLDs.

Canine chronic biliary tree disease (CBTD) is a suspected risk factor for pancreatic injury. The aim of this study was to evaluate the frequency and features of pancreatic involvement in canine CBTD, and their relationship with hyperlipemia and its severity. CBTD was defined as the increase in at least two of ALP, GGT, total bilirubin, cholesterol, and a biliary tree abnormal abdominal ultrasound (graded mild to severe). Pancreatic ultrasound appearance was recorded and classified as acute/chronic. Dogs were divided into a PBD group (pancreatic and biliary disease) and BD group (only biliary tree disease). PBD group was subgraded into a “pancreatic injury” and “pancreatitis” group. Eighty-one dogs were retrospectively included: 56 in the PBD group and 25 in the BD group. Of the PBD group, 20 had pancreatitis (15 chronic and 5 dogs acute). US score was mild in 64 dogs and moderate in 17 dogs, and it was not associated with evidence of pancreopathy. Sixty-six dogs had hyperlipemia (mild = 27 dogs; moderate-to-severe = 39 dogs) and no association with pancreopathy was found. Pancreatic injury was more frequent than pancreatitis in CBTD dogs. Although both acute and chronic pancreatic injury may be present, chronic forms were more frequent. Pancreatic injury should be considered in CBTD patients due its possible clinical significance.

Background: Water-soluble vitamin deficiencies are common in human chronic liver disease (CLD) due to impaired metabolic pathways. Vitamins B2 (riboflavin), B3 (niacin), and B5 (pantothenic acid) assume critical roles in hepatic and lipid metabolism and may exert hepatoprotective effects. In canine CLD, data beyond cobalamin are sparse, and no guidelines currently endorse B-vitamin supplementation. Methods: This case–control study analysed 66 stored serum samples from client-owned dogs with CLD and 50 from healthy blood-donor dogs. CLD diagnosis required persistent (>2 months) elevation of at least two liver enzymes (ALP, GGT, AST, ALT) and ultrasonographic evidence of CLD. Serum vitamin concentrations were quantified by LC-MS/MS (ng/mL). Results: Vitamin B2 was significantly lower in CLD dogs versus controls (median 48.4 vs. 85.5 ng/mL; p = 0.002). No significant difference was observed in B3 levels (p = 0.25). Vitamin B5 concentrations were significantly higher in the CLD group (median 176.5 vs. 116.1 ng/mL; p = 0.003). Conclusions: Reduced B2 may reflect impaired hepatic processing or absorption in canine CLD. The presence of normal or elevated B3 and B5 may relate to alternative metabolic pathways. This constitutes the first study assessing B2, B3, and B5 in canine CLD, underscoring riboflavin’s potential interest in CLD dogs.

The liver plays a central role in glucose and lipid metabolism. In human medicine, glucose metabolism alterations and insulin resistance are commonly associated with chronic liver disease (CLD), particularly in metabolic dysfunction–associated steatotic liver disease (MASLD). In veterinary medicine, however, the role of glucose metabolism in CLD remains poorly understood. We enrolled 67 client‐owned dogs, including healthy controls, hepatopathic dogs with (metabolic hepatopathy [MH]) or without (non‐metabolic hepatopathy [non‐MH]) metabolic factors such as overweight and hyperlipidemia, chronic kidney disease (CKD) dogs, and hyperlipidemic CKD (CKD HL) dogs. We measured serum liver enzymes, triglycerides, cholesterol, glucose, fructosamine, and insulin. Insulin resistance was assessed using the homeostasis model assessment for insulin resistance index (HOMA‐IR). Our findings revealed significantly elevated HOMA‐IR values in MH dogs compared to all other groups (median: MH—6.89; non‐MH—3.71; CKD—2.19; CKD HL—1.36; healthy—3.20). This increase occurred despite no significant differences in serum glucose and fructosamine concentrations. Results suggest the presence of insulin resistance in dogs with MH. HOMA‐IR was not correlated with liver biochemical parameters (ALT, ALP, and bilirubin) but showed a positive correlation with hypertriglyceridemia. As this is a pilot study, further research is needed to clarify the role of insulin resistance in canine hepatopathies.

Blood donor welfare is extensively studied in humans, while limited data exist for blood donor dogs. This multicentric prospective study aimed to evaluate physiological and behavioral responses in 89 canine blood donors. Clinical parameters (heart rate, respiratory rate, blood pressure, rectal temperature) and serum cortisol levels were measured before and after blood donation (BD), along with owner-reported behavioral assessments. Results showed no significant changes in cortisol concentrations pre-BD/post-BD or in most of the clinical parameters, except for rectal temperature that was significantly increased after BD [38.5 °C (38.2–39.4 °C) vs. 38.6 °C (37.6–41.7 °C), p < 0.001] suggesting a transient response likely due to physical restraint. No significant differences were found between first-time and repeat donors. Owners reported higher signs of arousal during the pre-donation phase, indicating anticipation as key to the stress response. However, more than 80% of the owners reported that their dogs behaved normally after the procedure and throughout the BD day. These findings suggest that canine whole BD is generally well tolerated and unlikely associated with systemic physiological stress. However, increased attention to the anticipatory phase, along with careful temperature monitoring, individualized restraint techniques, and optimized environmental management, may further improve canine blood donor welfare.